Pliant Therapeutics to Participate in Upcoming Investor Conferences
08 Novembro 2023 - 10:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage
biotechnology company and leader in the discovery and development
of novel therapeutics for the treatment of fibrotic diseases, today
announced participation in the following November investor
conferences.
- Stifel 2023 Healthcare
Conference Bernard Coulie, M.D., Ph.D., Pliant’s President
and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief
Medical Officer, will participate in a fireside chat on Wednesday,
November 15, 2023 at 1:15 pm Eastern Time.
- 6th Annual Evercore ISI
HealthCONx Conference Members of senior management will
meet with investors on Wednesday, November 29, 2023.
- Piper Sandler 35th Annual
Healthcare Conference Dr. Coulie and Dr. Lefebvre will
participate in a fireside chat on Thursday, November 30, 2023 at
9:00 am Eastern Time.
Interested parties may access the live webcasts of the Stifel
and Piper Sandler fireside chats by visiting the Investors &
Media page of Pliant’s website at www.PliantRx.com. Replays of the
webcast will be archived on the Pliant website for 30 days
following the conclusion of the events.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical
company and leader in the discovery and development of novel
therapeutics for the treatment of fibrotic diseases. Pliant's lead
product candidate, bexotegrast (PLN-74809), is an oral, small
molecule, dual selective inhibitor of αvß6 and αvß1 integrins that
is in development in the lead indications for the treatment of
idiopathic pulmonary fibrosis, or IPF, and primary sclerosing
cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical-stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social media
X, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Pliant Therapeutics (NASDAQ:PLRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024